DDR1 is a receptor tyrosine kinase (RTK)—a cell surface receptor—that regulates multiple functions including the maintenance of the normal structure of tissues, but which also contributes to pathological conditions including ...
Aug 9, 2019
0
3
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the ...
Jun 11, 2019
0
13
An important class of drug used to treat cancer patients could be used to treat brain aneurysms, according to new research published this week.
May 17, 2019
0
154
(HealthDay)—The selective Bruton's tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, ...
May 14, 2019
0
2
There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...
Apr 30, 2019
0
1
(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...
Apr 16, 2019
0
1
Relapse of disease following conventional treatments remains one of the central problems in cancer management, yet few therapeutic agents targeting drug resistance and tolerance exist. New research conducted at the Cancer ...
Apr 8, 2019
0
91
Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukemic stem cells persist ...
Mar 21, 2019
0
6
(HealthDay)—Almost half of elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) do not receive treatment, according to a study recently published in Leukemia & Lymphoma.
Mar 8, 2019
0
5
Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...
Feb 26, 2019
0
0
